Cargando…

SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma

BACKGROUND: Pancreatic adenocarcinoma (PAAD) is a treatment-refractory cancer with poor prognosis. Accumulating evidence suggests that squalene epoxidase (SQLE) plays a pivotal role in the development and progression of several cancer types in humans. However, the function and underlying mechanism o...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Weiqiang, Ke, Jia, Chen, Yufeng, Cai, Zerong, Huang, Ze-ping, Hu, Peishan, Wu, Xiaojian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204319/
https://www.ncbi.nlm.nih.gov/pubmed/35720314
http://dx.doi.org/10.3389/fimmu.2022.864244
_version_ 1784728898887483392
author You, Weiqiang
Ke, Jia
Chen, Yufeng
Cai, Zerong
Huang, Ze-ping
Hu, Peishan
Wu, Xiaojian
author_facet You, Weiqiang
Ke, Jia
Chen, Yufeng
Cai, Zerong
Huang, Ze-ping
Hu, Peishan
Wu, Xiaojian
author_sort You, Weiqiang
collection PubMed
description BACKGROUND: Pancreatic adenocarcinoma (PAAD) is a treatment-refractory cancer with poor prognosis. Accumulating evidence suggests that squalene epoxidase (SQLE) plays a pivotal role in the development and progression of several cancer types in humans. However, the function and underlying mechanism of SQLE in PAAD remain unclear. METHODS: SQLE expression data were downloaded from The Cancer Genome Atlas and the Genotype-Tissue Expression database. SQLE alterations were demonstrated based on the cBioPortal database. The upstream miRNAs regulating SQLE expression were predicted using starBase. The function of miRNA was validated by Western blotting and cell proliferation assay. The relationship between SQLE expression and biomarkers of the tumor immune microenvironment (TME) was analyzed using the TIMER and TISIDB databases. The correlation between SQLE and immunotherapy outcomes was assessed using Tumor Immune Dysfunction and Exclusion. The log-rank test was performed to compare prognosis between the high and low SQLE groups. RESULTS: We demonstrated a potential oncogenic role of SQLE. SQLE expression was upregulated in PAAD, and it predicted poor disease-free survival (DFS) and overall survival (OS) in patients with PAAD. “Amplification” was the dominant type of SQLE alteration. In addition, this alteration was closely associated with the OS, disease-specific survival, DFS, and progression-free survival of patients with PAAD. Subsequently, hsa-miR-363-3p was recognized as a critical microRNA regulating SQLE expression and thereby influencing PAAD patient outcome. In vitro experiments suggested that miR-363-3p could knock down the expression of SQLE and inhibit the proliferation of PANC-1. SQLE was significantly associated with tumor immune cell infiltration, immune checkpoints (including PD-1 and CTLA-4), and biomarkers of the TME. KEGG and GO analyses indicated that cholesterol metabolism-associated RNA functions are implicated in the mechanisms of SQLE. SQLE was inversely associated with cytotoxic lymphocytes and predicted immunotherapy outcomes. CONCLUSIONS: Collectively, our results indicate that cholesterol metabolism-related overexpression of SQLE is strongly correlated with tumor immune infiltration and immunotherapy outcomes in patients with PAAD.
format Online
Article
Text
id pubmed-9204319
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92043192022-06-18 SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma You, Weiqiang Ke, Jia Chen, Yufeng Cai, Zerong Huang, Ze-ping Hu, Peishan Wu, Xiaojian Front Immunol Immunology BACKGROUND: Pancreatic adenocarcinoma (PAAD) is a treatment-refractory cancer with poor prognosis. Accumulating evidence suggests that squalene epoxidase (SQLE) plays a pivotal role in the development and progression of several cancer types in humans. However, the function and underlying mechanism of SQLE in PAAD remain unclear. METHODS: SQLE expression data were downloaded from The Cancer Genome Atlas and the Genotype-Tissue Expression database. SQLE alterations were demonstrated based on the cBioPortal database. The upstream miRNAs regulating SQLE expression were predicted using starBase. The function of miRNA was validated by Western blotting and cell proliferation assay. The relationship between SQLE expression and biomarkers of the tumor immune microenvironment (TME) was analyzed using the TIMER and TISIDB databases. The correlation between SQLE and immunotherapy outcomes was assessed using Tumor Immune Dysfunction and Exclusion. The log-rank test was performed to compare prognosis between the high and low SQLE groups. RESULTS: We demonstrated a potential oncogenic role of SQLE. SQLE expression was upregulated in PAAD, and it predicted poor disease-free survival (DFS) and overall survival (OS) in patients with PAAD. “Amplification” was the dominant type of SQLE alteration. In addition, this alteration was closely associated with the OS, disease-specific survival, DFS, and progression-free survival of patients with PAAD. Subsequently, hsa-miR-363-3p was recognized as a critical microRNA regulating SQLE expression and thereby influencing PAAD patient outcome. In vitro experiments suggested that miR-363-3p could knock down the expression of SQLE and inhibit the proliferation of PANC-1. SQLE was significantly associated with tumor immune cell infiltration, immune checkpoints (including PD-1 and CTLA-4), and biomarkers of the TME. KEGG and GO analyses indicated that cholesterol metabolism-associated RNA functions are implicated in the mechanisms of SQLE. SQLE was inversely associated with cytotoxic lymphocytes and predicted immunotherapy outcomes. CONCLUSIONS: Collectively, our results indicate that cholesterol metabolism-related overexpression of SQLE is strongly correlated with tumor immune infiltration and immunotherapy outcomes in patients with PAAD. Frontiers Media S.A. 2022-05-26 /pmc/articles/PMC9204319/ /pubmed/35720314 http://dx.doi.org/10.3389/fimmu.2022.864244 Text en Copyright © 2022 You, Ke, Chen, Cai, Huang, Hu and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
You, Weiqiang
Ke, Jia
Chen, Yufeng
Cai, Zerong
Huang, Ze-ping
Hu, Peishan
Wu, Xiaojian
SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
title SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
title_full SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
title_fullStr SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
title_full_unstemmed SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
title_short SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
title_sort sqle, a key enzyme in cholesterol metabolism, correlates with tumor immune infiltration and immunotherapy outcome of pancreatic adenocarcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204319/
https://www.ncbi.nlm.nih.gov/pubmed/35720314
http://dx.doi.org/10.3389/fimmu.2022.864244
work_keys_str_mv AT youweiqiang sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma
AT kejia sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma
AT chenyufeng sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma
AT caizerong sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma
AT huangzeping sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma
AT hupeishan sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma
AT wuxiaojian sqleakeyenzymeincholesterolmetabolismcorrelateswithtumorimmuneinfiltrationandimmunotherapyoutcomeofpancreaticadenocarcinoma